会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • Methods for selecting treatment regimens and predicting outcomes in cancer patients
    • 选择治疗方案和预测癌症患者结局的方法
    • US20060084056A1
    • 2006-04-20
    • US10504287
    • 2003-02-13
    • Nadia HarbeckManfred SchmittJohn FoekensRonald Kates
    • Nadia HarbeckManfred SchmittJohn FoekensRonald Kates
    • C12Q1/68C12P19/34
    • C12Q1/6886C12Q2600/106C12Q2600/112C12Q2600/118C12Q2600/136G01N33/57415G01N2800/52Y02A90/26
    • The present invention relates to methods for determining a treatment regimen beyond surgical removal of tumor tissue for node negative or node positive breast cancer patient. The method comprises measuring the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in a subject, preferably a tumor; and, based upon the values, predicting the expected benefit including disease-free survival and/or overall survival for the patient without treatment (beyond the surgical removal of tumor tissue) or with a particular treatment and using that information to select a treatment regimen for the subject. High risk subject is identified by high levels of both uPA and PAI-1, high level of uPA and low level of PAI-1 or, low level of uPA and high level of PAI-1. Treatment options for high risk subjects include, but are not limited to, adjuvant CMF chemotherapy, adjuvant non-CMF chemotherapy, adjuvant endocrine therapy, adjuvant anthracyclin-containing chemotherapy, radiation therapy, and gene therapy. Treatment options for low risk subjects include, but are not limited to, no treatment, radiation, and adjuvant endocrine therapy.
    • 本发明涉及用于确定除了手术切除淋巴结阴性或淋巴结阳性乳腺癌患者的肿瘤组织之外的治疗方案的方法。 该方法包括测量受试者,优选肿瘤中尿激酶型纤溶酶原激活物(uPA)和纤溶酶原激活物抑制剂-1(PAI-1)的水平; 并且基于这些值,预测未经治疗的患者(超过手术切除肿瘤组织)或特定治疗的患者的无病生存期和/或总生存期的预期益处,并且使用该信息来选择治疗方案 主题。 uPA和PAI-1水平高,uPA水平高,PAI-1水平低,uPA水平低,PAI-1水平高。 高风险患者的治疗方案包括但不限于辅助性CMF化疗,辅助性非CMF化疗,辅助内分泌治疗,含蒽环类化疗,放射治疗和基因治疗。 低风险患者的治疗方案包括但不限于治疗,放射和辅助内分泌治疗。